Concepedia

Qinglin Pu

QP

Statistics

Publications

11

Citations

345

H-Index

10

Active since

1992

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Quantitative BioSciences

Discovery Laboratories (United States)

WuXi AppTec (China)

University of New Hampshire

Qinglin Pu is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicinal chemistry, drug discovery, and pharmacy.

ORCID

Publications per year

1992–2022

11

Publications

11

Discovery of Potent and Orally Available Bicyclo[1.1.1]pentane-Derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors

Qinglin Pu, Hongjun Zhang, Liangqin Guo et al. · ACS Medicinal Chemistry Letters · 2020 · 87 citations · Full text

, , +12

A New Class of Alkaloids from a Dendrobatid Poison Frog: A Structure for Alkaloid 251F

T. F. SPANDE, H. Martin Garraffo, Herman J. C. Yeh et al. · Journal of Natural Products · 1992 · 61 citations

, , +7

Discovery of Amino-cyclobutarene-derived Indoleamine-2,3-dioxygenase 1 (IDO1) Inhibitors for Cancer Immunotherapy

Hongjun Zhang, K. Liu, Qinglin Pu et al. · ACS Medicinal Chemistry Letters · 2019 · 44 citations · Full text

, , +16

Carbamate and <i>N</i>-Pyrimidine Mitigate Amide Hydrolysis: Structure-Based Drug Design of Tetrahydroquinoline IDO1 Inhibitors

Derun Li, Yongqi Deng, Abdelghani Achab et al. · ACS Medicinal Chemistry Letters · 2021 · 26 citations · Full text

, , +12

Structure-Based Discovery of Proline-Derived Arginase Inhibitors with Improved Oral Bioavailability for Immuno-Oncology

Min Lu, Hongjun Zhang, Derun Li et al. · ACS Medicinal Chemistry Letters · 2021 · 26 citations · Full text

, , +14

1–5 of 11